Merck KGaA has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.
The asset will be developed as a single agent as well as in various combinations with Pfizer’s and Merck KGaA, Darmstadt, Germany,’s broad portfolio of approved and investigational pipeline candidates.
The two companies will also combine resources and expertise to advance Pfizer’s anti-PD-1 antibody into Phase 1 trials.
As part of the agreement, Merck KGaA will co-promote Pfizer’s XALKORI, a medicine to treat non-small cell lung cancer, in the United States and several other key markets.
Merck KGaA, Darmstadt, Germany, will receive an upfront payment of $850 million (around € 680 million) and is eligible to receive regulatory and commercial milestone payments up to $ 2.0 billion.
Both companies will jointly fund all development and commercialization costs and all revenues obtained from selling any anti-PD-L1 or anti-PD-1 products generated from this collaboration will be shared.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends